Renin-Angiotensin System Inhibitors in COVID-19: Current Concepts.
Journal
International journal of hypertension
ISSN: 2090-0384
Titre abrégé: Int J Hypertens
Pays: United States
ID NLM: 101538881
Informations de publication
Date de publication:
2020
2020
Historique:
received:
21
04
2020
accepted:
17
09
2020
entrez:
4
11
2020
pubmed:
5
11
2020
medline:
5
11
2020
Statut:
epublish
Résumé
The functional receptor to SARS-CoV-2, the virus responsible for the coronavirus disease 2019 (COVID-19) pandemic, is angiotensin-converting enzyme-2 (ACE-2), the same enzyme that physiologically counters the renin-angiotensin system (RAS) activation. Some researchers have questioned RAS inhibitors' safety in COVID-19 patients since these drugs have demonstrated an increase in ACE-2 expression in preclinical studies; therefore, they may facilitate viral invasion. On the contrary, others have hypothesized a protective role of RAS inhibitors against COVID-19-associated lung injury. Overall, the data are grossly inadequate to reach any conclusion since no human trials have yet evaluated the effects of RAS inhibitors in COVID-19. We review the current data and pathophysiological mechanisms behind this intriguing interplay between the RAS inhibitors and the COVID-19.
Identifiants
pubmed: 33145103
doi: 10.1155/2020/1025913
pmc: PMC7596458
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1025913Informations de copyright
Copyright © 2020 Kunal Mahajan et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Lancet. 2020 May 30;395(10238):1705-1714
pubmed: 32416785
Circulation. 2019 May 7;139(19):2285-2288
pubmed: 30955360
JAMA Cardiol. 2020 Jul 1;5(7):811-818
pubmed: 32219356
Monaldi Arch Chest Dis. 2020 Apr 27;90(2):
pubmed: 32340429
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):253-254
pubmed: 32369103
J Am Coll Cardiol. 2020 May 12;75(18):2352-2371
pubmed: 32201335
Korean J Crit Care Med. 2017 May;32(2):154-163
pubmed: 31723629
J Am Heart Assoc. 2017 Feb 11;6(2):
pubmed: 28189999
JAMA Cardiol. 2020 Jul 1;5(7):802-810
pubmed: 32211816
Circulation. 2005 May 24;111(20):2605-10
pubmed: 15897343
Nat Med. 2005 Aug;11(8):875-9
pubmed: 16007097
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):723-724
pubmed: 32473902
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(3):135-136
pubmed: 32282032
J Card Fail. 2009 Sep;15(7):565-71
pubmed: 19700132
N Engl J Med. 2020 Apr 23;382(17):1653-1659
pubmed: 32227760
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Am J Hypertens. 2020 Oct 21;33(10):944-948
pubmed: 32511678
Proc (Bayl Univ Med Cent). 2018 Oct 26;31(4):419-423
pubmed: 30948970
Med J Armed Forces India. 2020 Jul;76(3):253-260
pubmed: 32773926
Clin Sci (Lond). 2020 Mar 13;134(5):543-545
pubmed: 32167153
BMJ. 2012 Jul 11;345:e4260
pubmed: 22786934
Am J Hypertens. 2015 Jan;28(1):15-21
pubmed: 24842388
Eur Heart J. 2020 May 14;41(19):1801-1803
pubmed: 32196087
Exp Physiol. 2008 May;93(5):631-8
pubmed: 18192334
Clin Sci (Lond). 2012 Dec;123(11):649-58
pubmed: 22715807
PLoS One. 2018 Jun 13;13(6):e0198144
pubmed: 29897923
JAMA Cardiol. 2020 Sep 1;5(9):1020-1026
pubmed: 32936273
Amino Acids. 2015 Apr;47(4):693-705
pubmed: 25534429
Hypertension. 2006 Oct;48(4):572-8
pubmed: 16908757
Sci China Life Sci. 2020 Mar;63(3):364-374
pubmed: 32048163
JAMA Cardiol. 2020 Jul 1;5(7):745-747
pubmed: 32242890
J Hypertens. 2012 Feb;30(2):375-83
pubmed: 22179088